Again, I want to be fair and include the counter arguments here before I make my case
Further reading FcRn blockade in CIDP (ADHERE trial) The Lancet Neurology 2024 #PatientEducation #CIDP #Neuromuscular #EvidenceBasedMedicine Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial thelancet.com To view or add a comment, sign in Platelet Hyperreactivity: A Novel Peripheral Biomarker for Preclinical Alzheimers
J Am Geriatr Soc 37:843847
Either way, starting the conversation is worthwhile
Tier 0 represents the starting dose range, typically used during the first four to eight weeks of treatment
L-Carnitine helps enhance exercise efficiency for body endurance